Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Immunotherapy in Squamous Cell Carcinoma of the Head and Neck
NCT03708224Phase 2Active, not recruiting
- Start
- Mar 2019
- Primary completion
- Jul 2027
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of atezolizumab in squamous cell carcinoma of the head and neck (HNSCC) (4 arms). Primary endpoints: Proportion of subjects with a >= 40% increase in the cluster of differentiation 3 (CD3) counts at 12 months and R0 resection rate at 12 months. Started Mar 2019; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT03708224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03708224.